Immunosuppressive effects of soluble factors secreted by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes

Oral Oncology

Volumn 39, Issue 7, 2003, Pages 672-679

  Kacani, Laco ^a   Wurm, Martin ^a   Schennach, Harald ^a   Braun, Ilona ^a   Andrle, Jan ^a   Sprinzl, Georg M ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Cytokines; Dendritic cells; Head and neck squamous cell carcinoma; Immunosuppression; Soluble factor; T lymphocytes

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4;

ANTIGEN PRESENTATION; ARTICLE; CELL CULTURE; CELL LINE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR CELL;

EID: 0042202336     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(03)00076-9     Document Type: Article

References (30)

1. Scully C., Field J.K., Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 36:2000;256-263.
2. Todryk S. A sense of tumour for the immune system. Immunology. 107:2002;1-4.
3. Steinman R.M., Dhodapkar M. Active immunization against cancer with dendritic cells. the near future Int J Cancer. 94:2001;459-473.
4. Urban J.L., Holland J.M., Kripke M.L., Schreiber H. Immunoselection of tumour cell variants by mice suppressed with ultraviolet radiation. J Exp Med. 156:1982;1025-1041.
5. Wortzel R.D., Urban J.L., Philipps C., Fitch F.W., Schreiber H. Independent immunodominant and immunorecessive tumour-specific antigens on a malignant tumour. antigenic dissection with cytolytic T cell clones J Immunol. 130:1983;2461-2466.
6. Hui K., Grosveld F., Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature. 311:1984;750-752.
7. Wallich R., Bulbuc N., Hammerling G.J., Katzav S., Segal S., Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature. 315:1985;301-305.
8. Restifo N.P., Esquivel F., Asher A.L.et al. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumour immune response. J Immunol. 147:1999;1453-1459.
9. Pardoll D.M. Cancer vaccines. Nat Med. 4:1998;525-531.
10. Staveley-O'Carroll K., Sotomayor E., Montgomery J.et al. Induction of antigen-specific T cell anergy: an early event in the course of tumour progression. Proc Natl Acad Sci USA. 95:1998;1178-1183.
11. Ohashi P.S., Oehen S., Buerki K.et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 65:1991;305-317.
12. Burkly L.C., Lo D., Kanagawa O., Brinster R.L., Flavell R.A. T-cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class II I-E. Nature. 342:1989;564-566.
13. Song E., Chen J., Ouyang N., Su F., Wang M., Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis. an active mode of immune evasion in colon cancer Br J Cancer. 85:2001;1047-1054.
14. Hahne M., Rimoldi D., Schroter M.et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumour immune escape. Science. 274:1996;1363-1366.
15. Gorelik L., Flavell R.A. Immune-mediated eradication of tumours through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 7:2001;1118-1122.
16. Kacani L., Frank I., Spruth M.et al. Dendritic cells transmit human immunodeficiency virus type 1 to monocytes and monocyte-derived macrophages. J Virol. 72:1998;6671-6677.
17. Liu Y.J., Kanzler H., Soumelis V., Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol. 2:2001;585-589.
18. Young M.R., Wright M.A., Lozano Y., Matthews J.P., Benefield J., Prechel M.M. Mechanisms of immune suppression in patients with head and neck cancer. influence on the immune infiltrate of the cancer Int J Cancer. 67:1996;333-338.
19. Reichert T.E., Rabinowich H., Johnson J.T., Whiteside T.L. Mechanisms responsible for signaling and functional defects. J Immunother. 21:1998;295-306.
20. Jonuleit H., Kuhn U., Muller G.et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 27:1997;3135-3142.
21. Okamoto M., Hiura K., Ohe G.et al. Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo. Cancer. 89:2000;1966-1975.
22. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 193:2001;233-238.
23. Hu H.M., Urba W.J., Fox B.A. Gene-modified tumour vaccine with therapeutic potential shifts tumour-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol. 161:1998;3033-3041.
24. Knerer B., Hulla W., Martinek H., Formanek M., Temmel A., Kornfehl J. IL-1 and TNF-alpha but no IL-2 expression is found in squamous cell carcinomas of the head and neck by RT-PCR. Acta Otolaryngol. 116:1996;132-136.
25. Sessions D.G., Spector G.J., Lenox J., Haughey B., Chao C., Marks J. Analysis of treatment results for oral tongue cancer. Laryngoscope. 112:2002;616-625.
26. Slootweg P.J., Hordijk G.J., Schade Y., van Es R.J., Koole R. Treatment failure and margin status in head and neck cancer. A critical view on the potential value of molecular pathology. Oral Oncol. 38:2002;500-503.
27. O'Brien C.J., Smith J.W., Soong S.J., Urist M.M., Maddox W.A. Neck dissection with and without radiotherapy: prognostic factors, patterns of recurrence, and survival. Am J Surg. 152:1986;456-463.
28. Sprinzl G.M., Hussl B., Obrist P.et al. Dendritic cells in precancerous lesions of the larynx. Laryngoscope. 110:2000;13-18.
29. Ochsenbein A.F., Sierro S., Odermatt B.et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 411:2001;1058-1064.
30. Gastman B.R., Atarshi Y., Reichert T.E.et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 59:1999;5356-5364.